On June 24, ANI said it was buying Alimera Sciences for $5.50 per share in cash, in a deal that valued Alimera at $381 million. The offer represented a 75% premium to its closing share price of $3.15 ...
Alimera Sciences has filed a lawsuit in the Delaware Court of Chancery to compel ANI Pharmaceuticals to fulfill its contractual obligation to close the transaction contemplated by the companies ...
A Nasdaq delisting notice last week indicated that the deal was tentatively scheduled to close on Monday after Alimera (ALIM) holders vote to approve the deal at a meeting on Sept. 4.
Results that may be inaccessible to you are currently showing.